Want to see ARMP full AI Analyst Report?
Top Page
Armata Pharmaceuticals
(NYSE MKT:ARMP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.50
▼(-3.43% Downside)
Action:Reiterated
Date:07/21/26
ARMP scores low primarily due to very weak financial performance (large ongoing losses, negative equity, and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events are a notable offset with meaningful regulatory progress and DoD support, but they do not fully counterbalance the current financial and trend risks; valuation is also limited by losses and no dividend yield data.
Positive Factors
Regulatory progress & Phase 3 readiness
FDA Fast Track and QIDP designations plus a submitted Phase 3 protocol and End‑of‑Phase‑2 responses materially reduce regulatory uncertainty. These durable developments enable more frequent agency interactions and potential accelerated review, improving the structural pathway to approval if pivotal results are positive.
Negative Factors
Stressed balance sheet / negative equity
Negative stockholders' equity is a structural red flag that limits financial flexibility and distorts leverage metrics. Persistent negative equity elevates refinancing and dilution risk, making it harder to secure favorable financing as the company undertakes expensive pivotal trials and commercialization preparations.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress & Phase 3 readiness
FDA Fast Track and QIDP designations plus a submitted Phase 3 protocol and End‑of‑Phase‑2 responses materially reduce regulatory uncertainty. These durable developments enable more frequent agency interactions and potential accelerated review, improving the structural pathway to approval if pivotal results are positive.
Read all positive factors
Armata Pharmaceuticals (ARMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$166.67M
Dividend YieldN/A
Average Volume (3M)213.69K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth10.70%
EPS Growth-66831.90%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.77
Shares Outstanding36,710,810
10 Day Avg. Volume216,533
30 Day Avg. Volume213,691
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside275.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$1.80M
Armata Pharmaceuticals Business Overview & Revenue Model
Company Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard ant...
How the Company Makes Money
As a clinical-stage biotechnology company, Armata Pharmaceuticals does not primarily generate recurring revenue from commercial product sales because its product candidates are in development and may not be approved for marketing. The company’s fu...
Armata Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.96M | 4.90M | 5.17M | 4.53M | 5.51M | 4.47M |
| Gross Profit | 2.13M | 3.37M | -29.25M | 3.56M | -29.51M | -15.54M |
| EBITDA | -262.46M | -155.68M | -6.85M | -65.45M | -36.00M | -21.92M |
| Net Income | -282.61M | -173.80M | -18.92M | -69.05M | -36.92M | -23.16M |
Balance Sheet | ||||||
| Total Assets | 69.80M | 76.88M | 86.44M | 98.36M | 107.88M | 69.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.75M | 8.69M | 9.29M | 13.52M | 14.85M | 10.29M |
| Total Debt | 373.67M | 288.02M | 126.52M | 120.37M | 48.81M | 37.99M |
| Total Liabilities | 381.39M | 295.48M | 134.46M | 130.43M | 71.80M | 44.37M |
| Stockholders Equity | -311.59M | -218.60M | -48.02M | -32.06M | 36.08M | 25.40M |
Cash Flow | ||||||
| Free Cash Flow | -24.47M | -26.30M | -39.43M | -55.57M | -34.69M | -24.88M |
| Operating Cash Flow | -23.96M | -25.76M | -37.55M | -47.42M | -32.48M | -23.57M |
| Investing Cash Flow | -506.00K | -542.00K | -1.88M | -8.13M | -2.21M | -1.30M |
| Financing Cash Flow | 16.27M | 25.61M | 34.96M | 53.99M | 44.02M | 25.52M |
Armata Pharmaceuticals Technical Analysis
Negative
4.66
Price Trends
6.03
Negative
8.00
Negative
7.58
Negative
Market Momentum
-0.35
Negative
43.62
Neutral
24.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Negative. The current price of 4.66 is above the 20-day moving average (MA) of 4.63, below the 50-day MA of 6.03, and below the 200-day MA of 7.58, indicating a neutral trend. The MACD of -0.35 indicates Negative momentum. The RSI at 43.62 is Neutral, neither overbought nor oversold. The STOCH value of 24.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARMP.
Armata Pharmaceuticals Risk Analysis
Armata Pharmaceuticals disclosed 30 risk factors in its most recent earnings report. Armata Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Armata Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $67.74M | 4.34 | 35.58% | ― | 93.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $159.57M | -0.68 | -67.65% | ― | 74.84% | 99.51% | |
43 Neutral | $166.67M | -0.58 | 162.59% | ― | 10.70% | -66831.90% | |
42 Neutral | $55.70M | -0.40 | -666.47% | ― | -100.00% | 46.40% |
* Healthcare Sector Average
ARMP
Armata Pharmaceuticals
4.70
2.34
99.15%
INO
Inovio Pharmaceuticals
0.67
-0.77
-53.26%
TNXP
Tonix Pharma
11.65
-35.27
-75.17%
SPRO
Spero Therapeutics
1.27
-0.90
-41.47%
Armata Pharmaceuticals Corporate Events
Executive/Board Changes
Armata Pharmaceuticals Promotes David House to CFO
Neutral
Jul 20, 2026
On July 17, 2026, Armata Pharmaceuticals’ board promoted David House to Chief Financial Officer, formalizing his role through a new employment letter agreement that took effect the same day. House, who had served as Senior Vice President, Fi...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
Positive
Jul 20, 2026
On July 20, 2026, Armata Pharmaceuticals reported notable progress across clinical, regulatory and manufacturing activities for AP-SA02, its intravenously administered multi-phage candidate for complicated Staphylococcus aureus bacteremia caused b...
Business Operations and StrategyRegulatory Filings and Compliance
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement
Positive
Jul 13, 2026
On July 13, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration had agreed to the company’s Initial Pediatric Study Plan for AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia in pa...
Business Operations and StrategyPrivate Placements and Financing
Armata gains new DoD funding for AP-SA02 advancement
Positive
Jun 23, 2026
On June 23, 2026, Armata Pharmaceuticals announced it received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense, bringing total DoD support to $28.7 million for its lead candidate AP-SA02. The bacteriophage-ba...
Executive/Board ChangesShareholder Meetings
Armata Shareholders Approve Directors, Executive Pay and Auditor
Positive
Jun 16, 2026
At its June 11, 2026 annual shareholder meeting, Armata Pharmaceuticals, Inc. shareholders elected seven directors, including Deborah L. Birx and Joseph M. Patti, to one-year terms expiring at the 2027 meeting. Shareholders also approved, on a non...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Armata Secures New Loan Amid Wider Quarterly Loss
Negative
May 13, 2026
On May 13, 2026, Armata reported first-quarter 2026 results and outlined plans to advance AP-SA02 into a Phase 3 superiority trial in complicated Staphylococcus aureus bacteremia in the second half of 2026, following FDA Fast Track and Qualified I...
Business Operations and StrategyProduct-Related Announcements
Armata Gains FDA Fast Track for AP-SA02 Therapy
Positive
May 7, 2026
On May 7, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track designation to AP-SA02, its intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.